+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Acino International AG - Strategic SWOT Analysis Review

Acino International AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Acino International AG (Acino), formerly Acino Holding AG, manufactures and commercializes generic and prescription pharmaceuticals in novel drug delivery forms. The company focuses on the therapeutic areas of oncology, cardiology and metabolism, central nervous system, gastroenterology, infectiology, pain and rheumatology, respiratory, urology and women’s health, among others. Acino also offers business-to-business services such as product development and contract manufacturing, among others. The company's drug delivery technologies focus on modified release oral forms and oral dispersible forms. Acino has manufacturing facilities in Estonia, South Africa, Dubai, Switzerland, and Ukraine. The company markets products mainly in the Middle East, Africa, Latin America, Europe, and Asia. Acino is headquartered in Zurich, Switzerland.

Acino International AG Key Recent Developments

  • Oct 08, 2024: Quality, Efficiency, Safety: Pharma Start Production Site in Ukraine Confirms EU GMP Certification
  • Apr 02, 2024: Acino Announces New Regional Leadership and Hub to Deliver on Expanded Presence and Capabilities in Latam Following M8 Acquisition Joel Barlan Appointed as Head of Latam Region

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Acino International AG - Key Facts
  • Acino International AG - Key Employees
  • Acino International AG - Key Employee Biographies
  • Acino International AG - Major Products and Services
  • Acino International AG - History
  • Acino International AG - Company Statement
  • Acino International AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Acino International AG - Business Description
  • Acino International AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Acino International AG - Strengths
  • Acino International AG - Weaknesses
  • Acino International AG - Opportunities
  • Acino International AG - Threats
  • Acino International AG - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Acino International AG, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Acino International AG, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Acino International AG, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Oct 08, 2024: Quality, Efficiency, Safety: Pharma Start Production Site in Ukraine Confirms EU GMP Certification
  • Apr 02, 2024: Acino Announces New Regional Leadership and Hub to Deliver on Expanded Presence and Capabilities in Latam Following M8 Acquisition Joel Barlan Appointed as Head of Latam Region
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Acino International AG, Key Facts
  • Acino International AG, Key Employees
  • Acino International AG, Key Employee Biographies
  • Acino International AG, Major Products and Services
  • Acino International AG, History
  • Acino International AG, Subsidiaries
  • Acino International AG, Key Competitors
  • Acino International AG, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Acino International AG, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Acino International AG, Recent Deals Summary
List of Figures
  • Acino International AG, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Acino International AG, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Basilea Pharmaceutica Ltd
  • Siegfried Holding AG
  • Wacker Biotech GmbH
  • Grunenthal GmbH
  • Actelion Pharmaceuticals Ltd